Representatives of these players offered their insights to Chinese biotech companies at the South Australia ∙ Clinical Trials Ecosystem – China Event Series zoom webinar on Sep. 13.
In the first half of 2021, nine Chinese drug developers completed initial public offerings (IPOs), raising an average of $243.4 million.
Improve the system of laws and regulations. Speed up their formulation and revision and advance technical guidelines in an orderly manner.
On July 1, 2020, the latest Drug Registration Regulations were enacted. This new set of regulations introduced four accelerated procedures for BTDs therapy, conditional approval, priority review and approval, and special approval.